Блокатори ренин-ангіотензин-альдостеронової системи: хронічна болезнь нирок і серцево-судинний ризик

D.D. Ivanov; O.V. Kuryata; I.P. Garmysh

doi:10.22141/2307-1257.7.2.2018.127393

Authors

D.D. Ivanov Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine http://orcid.org/0000-0003-2609-0051
O.V. Kuryata State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine http://orcid.org/0000-0001-7642-0077
I.P. Garmysh State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.7.2.2018.127393

Keywords:

chronic kidney disease, cardiovascular risks, combined antihypertensive therapy

Abstract

Reducing the risk of cardiovascular events is one of the most topical issues of modern medicine. Patients with chronic kidney disease stage 3 or lower, according to international guidelines, refer to the group with high and very high cardiovascular risk. At the moment, all the existing recommendations share the view that the first-line drugs for lowering blood pressure among this group of patients are renin-angiotensin-aldosterone system blockers. When renal and cardiovascular pathologies are combined, in addition to traditional risk factors, there are non-traditional kidney risk factors too (anaemia, hyperhydration, hypercoagulation, etc.). Combined antihypertensive therapy is preferable in order to achieve more significant reduction in global cardiovascular risk and closer control of blood pressure.

Downloads

Download data is not yet available.

References

Fedorova OA. Renin-angiotensin-aldosterone system-blokade in the management of the high-risk patients with comorbidity. Ukrainian Medical Journal. 2013;3(95):87-94. (in Russian).

Ivanov DD. Next step in chronic kidney disease therapy. Počki. 2016;(16):10-13. (in Russian).

Mancia G, Fagard R, Narkiewicz K, at al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul;34(28):2159-219. doi: 10.1093/eurheartj/eht151.

Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272.

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106.

Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 Nov 13. pii: HYP.0000000000000066. doi: 10.1161/HYP.0000000000000066.

Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. 2017 May;33(5):557-576. doi: 10.1016/j.cjca.2017.03.005.

Karpov IuA. Angiotensin-converting enzyme inhibitors and treatment of arterial hypertension. Praktikuiushchii vrach. 2002;(4):5-10. (in Russian).

Iabluchanskii NI. Arterial hypertension a new look at ACE inhibitors. Available from: http://medicusamicus.com/index.php?action=edpr-art_hyper_1.

Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2017 Oct 11;10:CD010315. doi: 10.1002/14651858.CD010315.pub2.

Zanchetti A, Liu L, Mancia G, et al. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016 Mar;34(3):393-6. doi: 10.1097/HJH.0000000000000853.

Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2009-20. doi: 10.1056/NEJMoa1600175.

Tsuji H, Shiojima I. Blood Pressure Lowering Less Than 130 mmhg is Best but Less Than 120 mmHg is Worst in a General Japanese Population. Circulation;2016;134(Suppl 1):A14133.

Zanchetti A, Liu L, Mancia G, et al. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016 Mar;34(3):393-6. doi: 10.1097/HJH.0000000000000853.

Gozhenko AI, Kravchuk AV, Nykytenko OP, Moskalenko OM, Sirman VM, authors; Gozhenko AI, editor. Funkcional'nyj nyrkovyj rezerv: monografija [Renal functional reserve: monograph]. Odesa: Feniks; 2015. 182 p. (in Ukrainian).

Ivanov DD, Savitska LM, Babenko ZV. Hyperuricemia and prognosis in chronic kidney disease. Počki. 2017;6(3):155-160. doi: 10.22141/2307-1257.6.3.2017.109031. (in Ukrainian).

Ivanov DD. Renin-angiotensin system antagonists, glomerular filtration rate and blood pressure. Počki. 2018;7(1):6-10. doi: 10.22141/2307-1257.7.1.2018.122214. (in Russian).

Kuryata OV, Кaikal DU. Cardiovascular risk in patients with chronic kidney disease, the role of dyslipidemia and the opportunity of statins. Ukrainian Journal of Nefrology and Dialysis. 2006;1(8):54-61. (in Russian).

Kuryata OV, Karapetjan KG, Bardachenko NI, Garmish IP. Possibilities of correction of cognitive functions and anxiety-depressive disorders in the complex therapy of arterial hypertension depending on the functional state of the kidneys. The Journal of Neuroscience of B.M. Mankovskyi. 2015;3(3):5-10. (in Russian).

Garmish IP, Kuryata OV. The effectiveness of multicomponent antihypertensive therapy in patients with chronic kidney disease in combinations with subclinical hypothyroidism. Family Medicine. 2017;3(71):22-27. (in Ukrainian).